We have now opened a prospective clinical study testing the safety and efficacy of the RT + IT-IC + anti-CTLA-4 in situ vaccine regimen in patients with metastatic melanoma (NCT03958383) and the potential role of the endogenous anti-tumor humoral response as a biomarker will be further investigated as part of that study. The gene discussed is CTLA4; the disease is metastatic melanoma.